Successful Treatment of Brunsting-Perry Cicatricial Pemphigoid With Dupilumab

We present the case of a 63-year-old patient with history of Brunsting-Perry cicatricial pemphigoid who proved refractory to multiple conventional therapies but was successfully treated with a dupilumab regimen of 300 mg every two weeks. This case suggests the potential role of dupilumab in the management of Brunsting-Perry cicatricial pemphigoid. J Drugs Dermatol. 2021;20(10):1113-1115. doi:10.36849/JDD.6032.PMID:34636516 | DOI:10.36849/JDD.6032
Source: Journal of Drugs in Dermatology - Category: Dermatology Authors: Source Type: research